CDC evaluation of the efficacy of monovalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection in 3 to 5-year-olds

The complete primary series monovalent mRNA vaccines protect children aged three to five against symptomatic infection for up to four months.